Patch Testing for XXXX and @entity16881 - @entity16880 Contact Allergy.

@entity1 @entity3408 @entity566 @entity5526 @entity16880 @entity1909 @entity16881
Importance: Contact @entity566 to @entity16880 (MI) or to the combined formulation of @entity16881 and MI (MCI-MI) has increased significantly, with a frequency of as much as 11.1% in @entity1 with @entity1909 ; however, few cohort studies in the US population have been reported. Objective: To investigate the prevalence of contact @entity566 to MI and MCI-MI and the outcomes of @entity1 with positive patch test reactions to MI and MCI-MI. Design, Setting, and @entity1 : Retrospective medical record review of all consecutive @entity1 (n   =   703) presenting with possible @entity3408 and subsequently undergoing patch testing at a tertiary referral center from January 1, 2012, through November 30, 2014. Patch testing used the North American @entity5526 Group standard series. The MCI-MI concentration was 100 ppm; the MI concentration in the screening series increased from 200 to 2000 ppm in January 2013. Demographic data, exposures, and outcomes were reported for @entity1 with positive patch test reactions to MI and/or MCI-MI. Data were analyzed from December 1, 2014, through January 31, 2015. Main Outcomes and Measures: Positive patch test reaction to MI and/or MCI-MI and identification of the relevance of contact @entity566 to these preservatives. Follow-up after allergen avoidance was determined when available. Results: Of the 703 @entity1 who underwent patch testing, contact @entity566 to MI and/or MCI-MI occurred in 57 @entity1 (8.1%), with 35 reactions to MI only, 5 reactions to MCI-MI only, and 17 reactions to both. Prevalence of contact @entity566 to MI increased from 6 of 236 @entity1 (2.5%) in 2012 to 16 of 235 @entity1 (6.8%) in 2014. The most commonly affected sites were the hands and face. Contact @entity566 to MI and/or MCI-MI was occupationally related in 4 cases. Cosmetics, soaps and cleansers (including wet wipes), and hair care products accounted for all identified sources. Twenty-three @entity1 had follow-up data, and 17 of these (74%) improved with allergen avoidance. Conclusions and Relevance: The increasing prevalence of contact @entity566 to MI alone supports its addition to the standard series to identify cases missed by testing only for MCI-MI. Recent regulations by the European Commission have banned MCI-MI in all leave-on body products as of July 16, 2015. Currently recommended US regulations are less stringent; however, US regulatory agencies must act to ensure @entity1 safety.
